IGY Life Sciences & Technology Inc. is a privately held Biotechnology Company specializing in the development, extraction and commercialization of antibodies, or immunoglobulin (IgY), for use as OTC nutraceuticals and for development of specific vaccines. The company was formed in 2009 to commercialize a superior proprietary process for extraction of avian immunoglobulin. IgY is a natural antibody for which there is an existing global demand.

Regentys (formerly Asana Medical) is focused on providing physicians with the first-in-class non-pharmacological, non-surgical treatment option for patients suffering from Ulcerative Colitis. Regentys’s device, derived from Extracellular Matrix, will set into motion a paradigm shift in the treatment of Inflammatory Bowel Disease (IBD) and other diseases from symptom-based, anti-inflammatory therapies to providing a protective coating to promote tissue healing.We are a GI-oriented company of highly motivated innovators, doctors, scientists, engineers, entrepreneurs, and professionals that identified an opportunity to apply existing Tissue Engineering Technology in a novel application. This will spark a change in the treatment of IBD and other GI diseases.

Helped to ensure a smooth transition of the Orphan Business Unit to the Group Vice President and General Manager taking on my previous role.

After the acquisition of Vidara Therapeutics by Horizon Pharma, I was responsible for integrating the Vidara business into Horizon. As Group Vice President and General Manager of the Orphan Business Unit, I was responsible for the P&L and leading the members of the Orphan Business Unit. In addition, I worked closely with the medical team to put into place the lifecycle management program for ACTIMMUNE® (interferon gamma-1b), including Fredreich’s Ataxia (currently in Phase III), Autosomal Dominant Osteopetrosis (currently in Phase II), renal/bladder cancer with PD-1 Inhibitors (currently in Phase I). In May of 2015, Horizon acquired Hyperion and I was responsible for the commercial due diligence during the deal process and then responsible for integrating the business into the Orphan Business Unit. Once we acquired Hyperion, I worked closely with the medical team to put into place the lifecycle program for RAVICTI® (glycerol phenylbutyrate). The Orphan Business Unit was over plan during my time at Horizon and we were able to further our mission of improving the lives of patients suffering from one of the orphan diseases we served (Chronic Granulomatous Disease, severe, malignant osteopetrosis, and patients suffering from certain urea cycle disorders.

As a member of the founding team and VP, Sales and Marketing, I was responsible for the commercial due diligence for the acquisition of ACTIMMUNE®, for developing the launch business plan, building the reimbursement HUB (COMPASS), for putting into place the high-touch specialty pharmacy network, for creating the marketing materials for the relaunch of ACTIMMUNE®, and for hiring and training the Clinical Sales Associates to cover the targeted accounts at launch. We were able to successfully grow the number of Chronic Granulomatous Disease & severe, malignant osteopetrosis patients by 40% and provide them with additional help to manage their/their loved one's disease. Vidara was acquired by Horizon Pharma in September 2014 for $600M.

As Division Sales Manager, I managed a team of 7 oncology representatives and was responsible for sales of PROVENGE® (sipuleucel-T) in the Greater Chicago Area which consisted of most of Illinois, Indiana and most of Kentucky. We worked with both urologists and oncologists to provide PROVENGE®, an autologous cellular immunotherapy, as a treatment option for their patients suffering from asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.

Worked closely with the CEO to conduct primary market research in the areas of pharmaceuticals, specialty pharmacy and managed care. After conducting the market research, worked to aggregate the information into a cohesive final report and recommendations to present to the client.

Responsible for the hospital and hematology products, including ATRYN® (antithrombin recombinant), PANHEMATIN® (hemin for injection) and NEOPROFEN® (ibuprofen lysine), as well as the commercial due diligence and launch planning on new product acquisitions. Our main products, ATRYN® and PANHEMATIN® both served ultra-orphan patient populations. We exceeded our corporate goals for these products and initiated targeted non-personal promotion campaign and an educational disease state campaign.

As the Director of Sales Training and Development, I was responsible for the CNS team product training for both XENAZINE® (tetrabenazine) and SABRIL® (vigabatrin), the area sales manager/director leadership development program, and compliance training for the commercial team. With my two training managers we develop the content for the launch meeting for SABRIL®, including workshops, the physician’s village and all the leaders’ guides.

As Product Director, CARDENE® I.V. (nicardipine I.V.), I was responsible for launching the CARDENE® I.V. line extension in the US during significant market change with two new market entrants a 505(b)(2) nicardipine and clevidipine emulsion. I developed the brand plan for launch of CARDENE® I.V (1x) RTU Bag.

Responsible for the sales of CARDENE® I.V. (nicardipine I.V.), RETAVASE® (reteplase), and I.V. BUSULFEX® (I.V. busulfan) in the Greater Chicago Region, consisting of 13 representatives and 8 states.

As a Regional Business Manager, I was responsible for the sales of CARDENE® I.V. (nicardipine I.V.), RETAVASE® (reteplase), and I.V. BUSULFEX® (I.V. busulfan) in the Greater Chicago Region, consisting of 13 representatives and 8 states. Prior to being promoted to Regional Business Manager, I relaunched Cardene I.V. in the Greater Chicago Area as one of the original ESP Pharma Hospital Sales Representatives.

As a field representative, I was responsible for the sales of DETROL® (tolterodine) (launch in 1998), VANTIN® (cefpodoxime proxetil), DEPO-PROVERA® (medroxyprogesterone), and LUVOX® (fluvoxamine) in the North and Northwest Suburbs of Chicago where in 1998 I won the Premier Award (top selling award). In 1999, I was promoted to Institutional Sales Representative where I was responsible for sales of FRAGMIN® (dalteparin) and ZYVOX® (linezolid) in the academic centers of Chicago.